
In addition, 12 other vaccine variants and brands have received authorization for limited emergency use for the core vaccine series. These include international options such as Sputnik-V, Moderna and Janssen, along with domestic options such as the DNA-based ZyCoV-D and nasal vaccine iNCOVACC.





